Premium
Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up
Author(s) -
Kahl Christoph,
Leisenring Wendy,
Joachim Deeg H.,
Chauncey Thomas R.,
Flowers Mary E. D.,
Martin Paul J.,
Sanders Jean E.,
Storb Rainer
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2005.05667.x
Subject(s) - medicine , cyclophosphamide , methotrexate , gastroenterology , regimen , aplastic anemia , surgery , globulin , chemotherapy , transplantation , lymphoma , cancer , bone marrow , immunology
Summary A total of 81 severe aplastic anaemia patients, aged 2–63 years, received human leucocyte antigen‐matched related marrow grafts after cyclophosphamide + antithymocyte globulin followed by postgrafting methotrexate + ciclosporin. Median follow‐up was 9·2 years. Ninety‐six per cent of patients had sustained engraftment, 24% developed acute graft‐ versus ‐host disease (GVHD), grade II in all but two patients, and 26% developed chronic GVHD; all surviving patients eventually responded to immunosuppressive therapy. Six patients developed cancer: one fatal lymphoma and five carcinomas (all five patients are now free of cancer). Survival was 88%. The regimen appeared well tolerated and effective in heavily pretreated patients with aplastic anaemia.